Equities research analysts at William Blair started coverage on shares of Immunic (NASDAQ:IMUX - Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set an "outperform" rating on the stock. William Blair also issued estimates for Immunic's FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.96 EPS.
Several other equities research analysts have also recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Immunic in a report on Friday, February 21st. D. Boral Capital reissued a "buy" rating and set a $17.00 price objective on shares of Immunic in a research note on Wednesday, February 26th. Finally, StockNews.com downgraded shares of Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Immunic presently has a consensus rating of "Buy" and an average price target of $12.67.
Check Out Our Latest Stock Analysis on IMUX
Immunic Stock Performance
Shares of IMUX stock traded down $0.04 on Tuesday, hitting $1.20. 653,857 shares of the company's stock traded hands, compared to its average volume of 604,174. The stock has a market capitalization of $108.09 million, a price-to-earnings ratio of -0.98 and a beta of 1.89. The company's fifty day simple moving average is $1.08 and its 200 day simple moving average is $1.21. Immunic has a one year low of $0.92 and a one year high of $2.11.
Institutional Trading of Immunic
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. Invesco Ltd. bought a new position in Immunic in the 4th quarter worth $37,000. Virtu Financial LLC purchased a new position in shares of Immunic during the third quarter valued at about $50,000. HB Wealth Management LLC bought a new position in Immunic in the fourth quarter worth about $81,000. Barclays PLC bought a new position in Immunic in the fourth quarter worth about $84,000. Finally, Jane Street Group LLC lifted its holdings in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after buying an additional 38,553 shares during the period. Hedge funds and other institutional investors own 51.82% of the company's stock.
Immunic Company Profile
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
See Also
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
